Suven Life Sciences is currently trading at Rs. 63.30, up by 1.30 points or 2.10 % from its previous closing of Rs. 62.00 on the BSE.
The scrip opened at Rs. 61.10 and has touched a high and low of Rs. 63.75 and Rs. 61.10 respectively. So far 121808 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 63.80 on 07-Nov-2013 and a 52 week low of Rs. 22.00 on 13-Jun-2013.
Last one week high and low of the scrip stood at Rs. 63.80 and Rs. 54.15 respectively. The current market cap of the company is Rs. 734.27 crore.
The promoters holding in the company stood at 64.76% while Institutions and Non-Institutions held 0.05% and 35.19% respectively.
Suven Life Sciences will be presenting positive pharmacology data of 4 advanced molecules from their portfolio of investigational neuroscience new chemical entities (NCEs) at SFN 2013 to be held at San Diego, USA during November 9-14, 2013. Key pharmacology, ADME and Safety data on selected NCEs, SUVN-G3031 (Histamine-3 receptor antagonist), SUVN-911 (Nicotinic acetylcholine alpha-4-beta-2 receptor antagonist), SUVN-D4010 (5-HT4 receptor partial agonist), SUVN-512 (5HT6 antagonists), CB2 agonist and M! modulators to treat the unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer’s, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain would be presented by Suven scientists at SFN-2013.
During SFN-2013 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore integrated collaborative research programs (CRP) and also Drug Discovery and Development Support Services (DDDSS) in addition to continued discussions with global Pharma majors regarding their clinical candidate SUVN-502.
Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this conference.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1814.50 |
| Dr. Reddys Lab | 1340.80 |
| Cipla | 1476.45 |
| Lupin | 2160.20 |
| Zydus Lifesciences | 972.95 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
